Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio Farma Offers Partnerships in Vaccine Development

Published: Monday, October 29, 2012
Last Updated: Monday, October 29, 2012
Bookmark and Share
Company to partner with vaccine manufacturers in developing and Islamic countries.

Indonesian vaccine-maker Bio Farma President Director Iskandar said the company he leads is ready to partner with vaccine manufacturers in developing and Islamic countries, particularly in the research and development of new vaccines.

"We hope that Bio Farma, as the only vaccine manufacturer in Indonesia, can be a hub or center for research and development of vaccines and serve as a partner to research new vaccines for developing countries," Iskandar told reporters in Bali on Sunday.

Iskandar made the statement as host of the 13th Developing Country Vaccine Manufacturers Networks (DCVMN) to be held in Bali on 31 October to 2 November 2012.

According to Iskandar, all vaccine producers in the world have the same ultimate goal, namely to increase the availability and quality of vaccines in order to achieve healthy communities.

He explained that the purpose of holding the DCVMN meeting is to jointly combat the spread of infectious diseases that are endemic in many developing countries.

This is to be achieved through increasing the capacity and quality of vaccines and improving vaccine research and development.

Iskandar said regular meetings of vaccine manufacturers in developing countries are needed to encourage the production and distribution of high-quality vaccines selectively in the long term to meet the targets of the national immunization program for these countries.

The Bio Farma president director said he had participated in the Global Health Product Development Conference 2012 in Seattle, 1-3 May 2012, where he gave a presentation on the achievements of Indonesia's only vaccine manufacturer, which is today 122 years old.

In the international meeting Iskandar explained Bio Farma has produced 11 types of vaccines and all have world-class recognition, namely the recognition of pre-qualification from the World Health Organization (WHO).

This fact interested partners of the Bill and Melinda Gates Foundation, the originator of the international meeting in Seattle, and many of them expressed interest in working with Bio Farma in conducting clinical trials and the development of vaccines, Iskandar pointed out.

The panelists at the meeting, among others represented, include Subhash Kapre (Serum Institute of India), Yang Xiaoming (China National Biotech Group), Akira Homma (Bio-Manguinhos), and Iskandar (Bio Farma).

The Bill and Melinda Gates Foundation is also scheduled to attend as a participant, represented by Dr. Kim Bush. More than 100 international vaccine researchers and experts have confirmed attendance at the conference.

DCVMN member countries are Argentina, Bangladesh, Brazil, Cuba, Egypt, India, Indonesia, Iran, Mexico, Republic of China, Republic of Korea, South Africa, Thailand and Vietnam.

DCVMN member companies and organizations are Beijing Minhai Biotechnology Bharat Biotech International Limited, Biological E. Limited, Bio-Manguinhos - Institute of Technology on Immunobiologicals, BioNet-Asia Co., Ltd., Cadila Pharmaceuticals Limited, Center for Genetic engineering and Biotechnology Chengda Liaoning, China National Biotec Group (CNBG).

Other members include EuBiologics, Finlay Institute, Haffkine, Hualan Bio, Incepta Ltd., Indian Immunologicals Limited, Institute of Vaccines and Medical Biologicals, Instituto Butantan, National Administration of Laboratories and Institute of Health ANLIS "Dr. Carlos G. Malbran."

Also represented are Panacea Biotec Ltd, Pasteur Institute of Iran, Bio Farma, Queen Saovabha Memorial Institute, Razi Vaccine & Serum Research Institute, Serum Institute of India Ltd, Sinergium, Sinovac Biotech Ltd., SK Chemicals, Biovac Institute, Company for Vaccine and Biological Production No.1 - Vabiotech, Government Pharmaceutical Organization-Holding Company for Biological Products & Vaccines (VACSERA), Tiantan, Walvax and Xiamen Innovax Biotech.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bio Farma Urges OIC Countries to Strengthen Vaccine Cooperation
Bio Farma to make OIC Countries self-reliance in vaccine industry.
Monday, June 17, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!